TY - JOUR
T1 - Albunex
T2 - A Safe and Effective Commercially Produced Agent for Myocardial Contrast Echocardiography
AU - Keller, Mark W.
AU - Glasheen, William
AU - Kaul, Sanjiv
N1 - Funding Information:
From the Division of Cardiology, Department of Medicine, University of Virginia School of Medicine. Supported in part by a grant-in-aid from the National Center of the American Heart Association, Dallas, with funds contributed in part by the Virginia Affiliate, Glen Allen, Virginia, and in part by a grant from Molecular Biosystems, Inc., San Diego. Dr. Keller is the recipient of a fellowship Grant F32-HL07502 from the National Institutes of Health, Bethesda, Maryland. Dr. Kaul is the recipient of the Clinical Investigator Award K08-HL-01833 and the FIRST Award R29-HL-38345 from the National Institutes of Health, Bethesda, Maryland. Reprint requests: Sanjiv Kaul, MD, Division of Cardiology, Box 158, University of Virginia School of Medicine, Charlottesville, VA 22908.
PY - 1989
Y1 - 1989
N2 - Microbubble solutions of sonicated human serum albumin have been shown to be effective echocardiographic contrast agents free from adverse effects on coronary blood flow, left ventricular function, and systemic hemodynamics. Albunex is a commercially prepared solution of air-filled albumin microspheres prepared from sonicated 5% human serum albumin. The effects of Albunex on coronary blood flow, left ventricular function, and systemic hemodynamics, as well as contrast enhancement were evaluated in 10 open chest, anesthetized dogs. After an intracoronary injection, Albunex did not alter left atrial, left ventricular systolic or end-diastolic, or mean` aortic pressures. It did not cause a coronary hyperemic response, alter left ventricular systolic thickening, or lower the peak positive left ventricular dp/dt. It did not alter these measurements even in the presence of a critical coronary stenosis. The contrast opacification produced by Albunex micro bubbles was dose dependent (optimal dose range of 0.033 to 0.5 ml/kg), with attenuation occurring at higher doses. In conclusion, although Albunex provides adequate contrast enhancement, intracoronary injection of Albunex does not significantly alter coronary blood flow, left ventricular function, or systemic hemodynamics. Because of the standardized size and concentration of the microspheres, Albunex may be an ideal agent for myocardial contrast echocardiography.
AB - Microbubble solutions of sonicated human serum albumin have been shown to be effective echocardiographic contrast agents free from adverse effects on coronary blood flow, left ventricular function, and systemic hemodynamics. Albunex is a commercially prepared solution of air-filled albumin microspheres prepared from sonicated 5% human serum albumin. The effects of Albunex on coronary blood flow, left ventricular function, and systemic hemodynamics, as well as contrast enhancement were evaluated in 10 open chest, anesthetized dogs. After an intracoronary injection, Albunex did not alter left atrial, left ventricular systolic or end-diastolic, or mean` aortic pressures. It did not cause a coronary hyperemic response, alter left ventricular systolic thickening, or lower the peak positive left ventricular dp/dt. It did not alter these measurements even in the presence of a critical coronary stenosis. The contrast opacification produced by Albunex micro bubbles was dose dependent (optimal dose range of 0.033 to 0.5 ml/kg), with attenuation occurring at higher doses. In conclusion, although Albunex provides adequate contrast enhancement, intracoronary injection of Albunex does not significantly alter coronary blood flow, left ventricular function, or systemic hemodynamics. Because of the standardized size and concentration of the microspheres, Albunex may be an ideal agent for myocardial contrast echocardiography.
UR - http://www.scopus.com/inward/record.url?scp=0024351314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024351314&partnerID=8YFLogxK
U2 - 10.1016/S0894-7317(89)80028-8
DO - 10.1016/S0894-7317(89)80028-8
M3 - Article
C2 - 2627424
AN - SCOPUS:0024351314
SN - 0894-7317
VL - 2
SP - 48
EP - 52
JO - Journal of the American Society of Echocardiography
JF - Journal of the American Society of Echocardiography
IS - 1
ER -